1. Aide
    1. Espace Client
    2. Connexion
Espace Membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre


Conserver cet article pour le lire plus tard


Ce service est réservé aux clients et membres de Boursorama.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

Transgene Schedules Conference Call to Discuss 2013 Financial Results
Boursorama25/03/2014 à 17:15


 Transgene Schedules Conference Call to Discuss 2013 Financial Results



Strasbourg, France, March 25, 2014 - Transgene SA (NYSE-Euronext: TNG) today announced that the Company will hold a conference call to discuss financial results for fiscal year 2013 and to provide a business update. The results will be published on March 26, 2014 in advance of the call.


The conference call, which will be conducted in English, will be held on Wednesday, March 26, 2014 at 1 PM EDT/6 PM CET.  A replay of the call will be available on the Transgene website (www.transgene.fr) following the live event.



Webcast link:




Webcast access on mobile devices - QR code:




Participant telephone numbers:


France:                        +33 (0)1 70 99 42 76

United Kingdom:        +44 (0)20 3427 1901

US:                               +1 212 444 0895


Confirmation Code:  5911562


Participants will need to provide the above code when dialing into the call.




About Transgene


Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company’s four clinical-stage programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver cancer; TG4001 for oropharyngeal cancer (under a collaboration agreement with the EORTC) and TG4040 for chronic Hepatitis C. Transgene has concluded corporate strategic agreements for the development of two of its immunotherapy products: an exclusive option agreement with Novartis for the development and commercialization of TG4010 and an in-licensing agreement with U.S.-based Jennerex, Inc. for the development and commercialization of Pexa-Vec in certain territories.  The Company also has several programs in research and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.  Additional information about Transgene is available at www.transgene.fr.




For media: MC Services

Elisabetta Castelli, Director IR

Raimund Gabriel

+33 (0)3 88 27 91 21

+49 89 210 228 30



Laurie Doyle, Director IR US & Corporate Communications


+1 (339) 832 0752

Shaun Brown


+44 207 148 5998




Valeurs associées


0 commentaire

Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

Signaler le commentaire


Mes listes

Une erreur est survenue pendant le chargement de la liste




Les Risques en Bourse